NCT04819399 - Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2023

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG

Catumaxomab

"Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~1. cohort 50 µg~2. cohort 70 µg~3. cohort 100 µg~Part II will be treated at recommended dose"

Trial Locations (1)

Unknown

RECRUITING

Urologie Planegg, München